Генетический полиморфизм лекарственного метаболизма как предиктор клинической эффективности фармакотерапии больных язвенной болезнью, ассоциированной с Н. Pylori

Pharmacogenetic studies have established the heterogeneity of the human population in the ability to metabolize drugs, including proton pump inhibitors. Considered a personalized approach to the selection of antisecretory therapy in patients with peptic ulcer disease associated with H. pylori, depending on the genetic variability of genes regulating drug metabolism. In the study of polymorphism of CYP2C19 * 2 found that 71,43 ± 2,64% of patients with peptic ulcer have rapid genotype, 18,37 ± 2,6% intermediate, 10,2 ± 1,77% slow metabolizers. Based on these results, we construct economic models allowing for the pharmacotherapy of pharmacogenetic profile and direct treatment costs. A model in which the initial phase of treatment is assigned a double dose of omeprazole or lansoprazole, despite the high cost, requires a higher efficacy.